China JoJo Drugstores (CJJD)
(Delayed Data from NSDQ)
$1.60 USD
0.00 (0.00%)
Updated Sep 20, 2024 11:50 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for China JoJo Drugstores Holdings Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 155 | 149 | 164 | 133 | 117 |
Cost Of Goods | NA | NA | NA | 104 | 92 |
Gross Profit | NA | NA | NA | 29 | 26 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 0 | 0 | 38 | 32 |
Income After Depreciation & Amortization | 0 | 0 | 0 | -9 | -6 |
Non-Operating Income | NA | NA | NA | 1 | 1 |
Interest Expense | NA | NA | NA | 0 | 1 |
Pretax Income | NA | NA | NA | -8 | -6 |
Income Taxes | NA | NA | NA | 0 | 0 |
Minority Interest | NA | NA | NA | 0 | -1 |
Investment Gains/Losses | NA | NA | NA | 0 | 0 |
Other Income/Charges | NA | NA | NA | 0 | 0 |
Income From Cont. Operations | -4 | -21 | -3 | -8 | -6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -4 | -21 | -3 | -8 | -6 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 0 | 0 | -7 | -4 |
Depreciation & Amortization (Cash Flow) | NA | NA | NA | 2 | 2 |
Income After Depreciation & Amortization | 0 | 0 | 0 | -9 | -6 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 1.44 | 0.51 | 0.17 | 0.17 | 0.14 |
Diluted EPS Before Non-Recurring Items | -2.93 | -41.40 | -18.40 | -48.02 | -43.22 |
Diluted Net EPS (GAAP) | -2.93 | -41.40 | -18.40 | -48.02 | -43.22 |
Fiscal Year end for China JoJo Drugstores Holdings Inc falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |